AIGH Capital Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

AIGH Capital Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,100,000	Closed	-$8.82M	–	62
2023 Q1	$8.82M	Buy	2,100,000 +694,141	+49%	+$3.6M	3.25%	11
2022 Q4	$8.45M	Buy	+1,405,859	New	+$7.67M	2.78%	14

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

AIGH Capital Management's CTIC Position: Q2 2023 in Review

AIGH Capital Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 2,100,000 shares — an estimated $8.82M sold.

AIGH Capital Management first reported a position in CTIC in Q4 2022 and held it in 2 quarters. The position peaked at $8.82M in Q1 2023. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

AIGH Capital Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
AIGH Capital Management sold 2,100,000 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $8.82M.
AIGH Capital Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2022 and held it in 2 quarters.
AIGH Capital Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $8.82M in Q1 2023.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on AIGH Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.